207 related articles for article (PubMed ID: 20381119)
1. CD147 expression in pituitary adenomas and its significance for clinical outcome.
Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
[TBL] [Abstract][Full Text] [Related]
3. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
4. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
[TBL] [Abstract][Full Text] [Related]
5. [Expression of MMPPs and TIMP and invasiveness in pituitary adenomas].
Wang J; Liu YS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):647-50. PubMed ID: 16114548
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of folate receptor alpha in pituitary adenomas and its relationship to tumor behavior.
Liu X; Ma S; Yao Y; Li G; Feng M; Deng K; Dai C; Cai F; Li Y; Zhang B; Wang R
Neurosurgery; 2012 May; 70(5):1274-80; discussion 1280. PubMed ID: 22089756
[TBL] [Abstract][Full Text] [Related]
8. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication.
Yu W; Liu J; Xiong X; Ai Y; Wang H
Pathol Res Pract; 2009; 205(10):709-15. PubMed ID: 19541433
[TBL] [Abstract][Full Text] [Related]
9. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma.
Zhang Y; He N; Zhou J; Chen Y
Clin Imaging; 2011; 35(3):165-73. PubMed ID: 21513851
[TBL] [Abstract][Full Text] [Related]
10. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
11. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
12. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
13. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
14. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
[TBL] [Abstract][Full Text] [Related]
15. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
Lath R; Chacko G; Chandy MJ
Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Jpn J Clin Oncol; 2008 Aug; 38(8):528-33. PubMed ID: 18664479
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma.
Zhang Q; Zhou J; Ku XM; Chen XG; Zhang L; Xu J; Chen GS; Li Q; Qian F; Tian R; Wen N; Chen ZN
Eur J Cancer Prev; 2007 Jun; 16(3):196-202. PubMed ID: 17415090
[TBL] [Abstract][Full Text] [Related]
19. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
Gejman R; Swearingen B; Hedley-Whyte ET
Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
[TBL] [Abstract][Full Text] [Related]
20. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
